Zacks Investment Research upgraded shares of Lantheus (NASDAQ:LNTH) from a hold rating to a buy rating in a report released on Friday morning. The firm currently has $26.00 target price on the medical equipment provider’s stock.

According to Zacks, “Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It serves to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, radiopharmacies and wholesalers. Lantheus Holdings, Inc. is based in NORTH BILLERICA, United States. “

Other equities analysts also recently issued research reports about the stock. BidaskClub downgraded shares of Lantheus from a buy rating to a hold rating in a report on Tuesday, December 19th. ValuEngine lowered Lantheus from a buy rating to a hold rating in a research report on Friday, December 1st. Credit Suisse Group upped their target price on Lantheus from $19.00 to $23.00 and gave the company a neutral rating in a research report on Friday, November 3rd. Jefferies Group reiterated a buy rating and issued a $22.00 target price on shares of Lantheus in a research report on Thursday, October 12th. Finally, Wells Fargo & Co upgraded Lantheus from a market perform rating to an outperform rating in a research report on Thursday, November 2nd. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of Buy and an average price target of $24.50.

Lantheus (NASDAQ:LNTH) traded down $0.17 on Friday, hitting $23.48. 214,200 shares of the stock traded hands, compared to its average volume of 311,822. Lantheus has a 12-month low of $7.95 and a 12-month high of $24.10. The company has a current ratio of 2.96, a quick ratio of 2.46 and a debt-to-equity ratio of -3.41. The firm has a market capitalization of $880.45 and a P/E ratio of 29.35.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, November 2nd. The medical equipment provider reported $0.24 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.04. Lantheus had a net margin of 9.59% and a negative return on equity of 46.45%. The firm had revenue of $79.94 million for the quarter, compared to the consensus estimate of $77.18 million. During the same quarter in the prior year, the company posted $0.15 earnings per share. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. research analysts expect that Lantheus will post 1.05 EPS for the current fiscal year.

In related news, insider Michael P. Duffy sold 11,917 shares of the company’s stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $21.63, for a total value of $257,764.71. Following the sale, the insider now owns 152,301 shares in the company, valued at $3,294,270.63. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Michael P. Duffy sold 21,655 shares of the company’s stock in a transaction that occurred on Wednesday, January 10th. The stock was sold at an average price of $22.40, for a total value of $485,072.00. Following the completion of the sale, the insider now owns 156,784 shares in the company, valued at approximately $3,511,961.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 44,886 shares of company stock worth $986,201. 2.30% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in LNTH. Vanguard Group Inc. boosted its position in Lantheus by 87.5% in the 2nd quarter. Vanguard Group Inc. now owns 1,478,350 shares of the medical equipment provider’s stock worth $26,093,000 after purchasing an additional 689,954 shares in the last quarter. State Street Corp boosted its position in Lantheus by 3,932.8% in the 2nd quarter. State Street Corp now owns 617,014 shares of the medical equipment provider’s stock worth $10,891,000 after purchasing an additional 601,714 shares in the last quarter. Peregrine Capital Management LLC purchased a new stake in Lantheus in the 3rd quarter worth approximately $8,062,000. Ameriprise Financial Inc. purchased a new stake in Lantheus in the 2nd quarter worth approximately $7,396,000. Finally, JPMorgan Chase & Co. boosted its position in Lantheus by 3,290.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 429,518 shares of the medical equipment provider’s stock worth $7,582,000 after purchasing an additional 416,849 shares in the last quarter. Institutional investors and hedge funds own 91.91% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was published by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://www.watchlistnews.com/lantheus-lnth-upgraded-at-zacks-investment-research-2/1808108.html.

About Lantheus

Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.

Get a free copy of the Zacks research report on Lantheus (LNTH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with Analyst Ratings Network's FREE daily email newsletter.